Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05903066

TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD).

Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Liège, Liège, Belgium

Loading trial locations.

About this study

Number of patients : 210 patients, in 14 sites (only one investigator per site), 15 patients per site, 5 patients per grade of transmural healing based on the appraisal of a local reader pair (a gastroenterologist and a radiologist).

Recruitment period : 2 years

Primary Endpoint : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD

Secondary Endpoints :

  • To analyze intra- and inter-observer variability of radiological findings.
  • To analyze intra- and inter-observer variability of TH definitions in CD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years of age
  • Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record.
  • Indication for MRE based on routine clinical practice validated by the treating physician
  • Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…).
  • The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study.
  • A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.

Exclusion criteria

  • Pregnancy during the study
  • People unable to give consent (because of their physical or mental state)
  • Absence of written consent
  • Ulcerative colitis or unclassified IBD
  • Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy.
  • Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve)
  • Severe obstructive symptoms
  • Symptomatic intra-abdominal abscess
  • Contraindication for MRI
  • Isolated perianal disease without luminal location
  • MRE images of poor quality, based on previously defined criteria

Treatment and study plan

Magnetic Resonance Enterography (MRE)

Procedure

MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.

Primary outcomes

  1. Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD

    Time frame: Day 1

    An index (depth of remission) or score (grade of remission) will be constructed through multiple linear or logistic mixed regression models.

Secondary outcomes

  1. Intra- and inter-observer variability of lesions observed per segment during MRE in CD

    Time frame: Day 1

    Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.

  2. Intra- and inter-observer variability of depth and grade of global transmural healing in CD

    Time frame: Day 1

    Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.

Study contacts

Contact information is provided by the study sponsor or research team.

Laurent PEYRIN-BIROULET

CONTACT

[email protected]

+33 3 83 15 36 61

Sophie GEYL

CONTACT

[email protected]

+33 5 55 05 66 31

Sponsors and collaborators

Lead sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Other

Registry information

Official study title

TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study

Acronym: TRENCH 1

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 15, 2023
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.